The validation of prostate specific membrane antigen (PSMA) as a molecular target in
metastatic castration-resistant prostate cancer has stimulated the development of multiple …

Prostate-specific membrane antigen (PSMA) is a credentialed imaging and therapy
(theranostic) target for the detection and treatment of prostate cancer. PSMA-targeted PET …

Although prostate cancer is the type of cancer most commonly survived by men in the United
States, it remains the second most common cause of death from cancer, largely owing to …

Despite significant advances in nuclear medicine for diagnosing and treating prostate
cancer (PCa), research into new ligands with increasingly better biological properties is still …

Hintergrund Das prostataspezifische Membranantigen (PSMA) ist für
Mammakarzinompatientinnen ein vielversprechendes Protein. Es wurde bisher nicht nur …

Objective To systematically review the prospective literature on the role of 68 Ga and 18 F
PSMA PET/CT and PET/MRI as a tool for functional imaging in prostate cancer biochemical …

Cancer is one of the leading social problems of the modern world. Today prostate cancer is
the second leading cause of cancer deaths among men. Targeted drug delivery is widely …

Purpose SABR has demonstrated clinical benefit in oligometastatic prostate cancer.
However, the risk of developing new distant metastatic lesions remains high, and only a …

Glutamate carboxypeptidase-II (GCPII) is a zinc-dependent metalloenzyme implicated in
numerous neurological disorders. The pharmacophoric requirements of active-site GCPII …

The rapidly evolving clinical utility of prostate-specific membrane antigen (PSMA) PET/CT as
an imaging modality for prostate cancer (PCa) has brought to the forefront a multitude of non …